SYBX - Synlogic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0200
-0.2100 (-6.50%)
As of 12:44PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.2300
Open3.2100
Bid3.0100 x 1000
Ask3.0200 x 900
Day's Range2.9057 - 3.3100
52 Week Range2.9057 - 14.5900
Volume339,930
Avg. Volume241,179
Market Cap95.79M
Beta (3Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-1.8610
Earnings DateNov 11, 2019 - Nov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.83
Trade prices are not sourced from all markets
  • Synlogic Discontinues Development of SYNB1020, Stock Down
    Zacks

    Synlogic Discontinues Development of SYNB1020, Stock Down

    Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.

  • MarketWatch

    Synlogic's stock sinks toward record low after SYNB1020 development discontinued as trial disappoints

    Shares of Synlogic Inc. tumbled 17% toward a record low in premarket trading Tuesday, after the biotechnology company said it has discontinued the development of SYNB1020 for the treatment of hyperammonemia following disappointing trial results. The company said that data from a phase1b/2a study showed that while SYNB1020 was well tolerated in patients with cirrhosis, there was no evidence of blood ammonia lowering or changes in other exploratory endpoints relative to placebo. "Moving forward, we will focus our resources on advancement of SYNB1618 for the treatment of phenylketonuria, SYNB1891 for the treatment of solid tumors and several new programs in early development," said Chief Executive Aoife Brennan. The stock has tumbled 31.1% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has gained 10.1% and the S&P 500 has advanced 16.6%.

  • Benzinga

    The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 19) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Avid ...

  • Business Wire

    Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia

    Synlogic, Inc., (SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced that it is discontinuing development of SYNB1020, an early stage clinical product candidate for the treatment of hyperammonemia. The decision to discontinue the program was based on top-line data from an interim analysis of a randomized, double-blind, placebo-controlled Phase 1b/2a study of the Synthetic Biotic medicine in 23 patients with cirrhosis and elevated blood ammonia. The study was designed to evaluate the safety and tolerability of SYNB1020 treatment, as well as changes in blood ammonia levels and several exploratory endpoints associated with early stage hepatic encephalopathy (HE).

  • Thomson Reuters StreetEvents

    Edited Transcript of SYBX earnings conference call or presentation 8-Aug-19 9:00pm GMT

    Q2 2019 Synlogic Inc Earnings Call

  • Business Wire

    Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference

    Synlogic, Inc. (SYBX) announced today that Scott Plevy, M.D., Synlogic’s chief scientific officer, will provide a corporate update at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13 at 9:45 am ET, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease.

  • Business Wire

    Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates

    – Strong balance sheet supports clinical advancement of lead and emerging Synthetic Biotic™ programs –

  • Microbiome biotechs grapple with how to protect their IP
    American City Business Journals

    Microbiome biotechs grapple with how to protect their IP

    Microbiome companies face an added complication that other drugmakers may not when trying to maintain an exclusive hold on their products: It’s not possible to patent a naturally occurring substance like plants or bacteria.

  • Business Wire

    Synlogic Announces Second Quarter 2019 Conference Call and Webcast

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its second quarter 2019 financial results after the market closes on Thursday, August 8, 2019. The press release will be followed by a conference call at 5:00 pm ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

  • Synlogic Enters Oversold Territory
    Zacks

    Synlogic Enters Oversold Territory

    Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Business Wire

    Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development

    Synlogic, Inc., (SYBX), a clinical stage company developing a novel class of Synthetic BioticTM therapeutics, today announced positive top-line clinical data from patient cohorts of a randomized, double-blind, placebo-controlled Phase 1/2a study of SYNB1618, which is being developed for the treatment of phenylketonuria (PKU). The study’s primary objectives were to evaluate safety and tolerability of an early liquid formulation. Exploratory outcomes were related to the assessment of the pharmacodynamic effects of SYNB1618, including measurement of previously identified biomarkers related to SYNB1618’s engineered ability to consume phenylalanine (Phe).

  • Zacks Small Cap Research

    American Gene Technologies: The Software Revolution for the Next 100 Years

    By John Vandermosten, CFA American Gene Technologies (AGT) is a genetic medicines company developing a portfolio of therapies that employ the company’s proprietary lentiviral vector (LV) platform to focus ...

  • Business Wire

    Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines

    Synlogic, Inc. (SYBX), a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines and Ginkgo Bioworks, the organism company, today announced a platform collaboration to accelerate expansion and development of Synlogic’s pipeline of Synthetic Biotic medicines using Ginkgo’s cell programming platform.

  • Synlogic (SYBX) Enters Cancer Collaboration with Roche
    Zacks

    Synlogic (SYBX) Enters Cancer Collaboration with Roche

    Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.

  • Business Wire

    Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Biotic™ medicine, SYNB1891, a dual innate immune activator engineered to express a STING agonist, in combination with Roche’s PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab (Tecentriq®) in patients with advanced solid tumors. Synlogic expects to file an Investigational New Drug (IND) application with the U.S. Federal Drug Administration (FDA) in the second half of 2019 for SYNB1891 to enable the company to begin an open-label Phase 1 clinical trial to evaluate the candidate as a monotherapy and a combination treatment with atezolizumab.

  • Synlogic, Inc. (SYBX) Q1 2019 Earnings Call Transcript
    Motley Fool

    Synlogic, Inc. (SYBX) Q1 2019 Earnings Call Transcript

    SYBX earnings call for the period ending March 31, 2019.

  • Thomson Reuters StreetEvents

    Edited Transcript of SYBX earnings conference call or presentation 9-May-19 9:00pm GMT

    Q1 2019 Synlogic Inc Earnings Call

  • Business Wire

    Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update

    – Company will host a conference call and webcast at 5:00 pm ET today –

  • Business Wire

    Synlogic Announces First Quarter 2019 Conference Call and Webcast

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market closes on Thursday, May 9, 2019. The press release will be followed by a conference call at 5:00 pm ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

  • Business Wire

    Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced that data demonstrating its development of a robust and reproducible process to generate a solid oral formulation of its Synthetic Biotic medicine, SYNB1618, are being presented today at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). Synlogic is developing SYNB1618 for the treatment of phenylketonuria (PKU).

  • Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer
    Investor's Business Daily

    Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer

    Big Pharma is rapidly increasing its investments into biotech companies aiming to treat disease by targeting the microbiome. Some are also working on using bacterial strains as drugs.

  • Could Synlogic, Inc.'s (NASDAQ:SYBX) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Synlogic, Inc.'s (NASDAQ:SYBX) Investor Composition Influence The Stock Price?

    A look at the shareholders of Synlogic, Inc. (NASDAQ:SYBX) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders...

  • Business Wire

    Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

    Synlogic, Inc., (SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of its Synthetic BioticTM medicines will be presented at the upcoming 22nd Annual Meeting of the American Society of Gene & Cell Therapy, which is being held from April 29 to May 2, 2019, in Washington, DC. The presentation will focus on preparation and characteristics of a solid oral preparation of SYNB1618, Synlogic’s synthetic biotic medicine for the treatment of phenylketonuria (PKU). Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer
    Business Wire

    Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer

    Synlogic, Inc. (SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy, M.D., as Chief Scientific Officer. Dr. Plevy will have responsibility for Synlogic’s research organization and will report to Aoife Brennan, M.B., Ch.B., Synlogic’s president and chief executive officer.

  • Business Wire

    Synlogic to Webcast Presentation at the 18th Annual Needham Healthcare Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease.